Top ▲

B cell maturation antigen

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1889

Nomenclature: B cell maturation antigen

Abbreviated Name: BCMA

Systematic Nomenclature: TNFRSF17

Family: Tumour necrosis factor (TNF) receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 184 16p13.13 TNFRSF17 TNF receptor superfamily member 17
Mouse 1 185 16 A1 Tnfrsf17 tumor necrosis factor receptor superfamily, member 17
Rat - - Tnfrsf17 TNF receptor superfamily member 17
Previous and Unofficial Names Click here for help
tumor necrosis factor receptor superfamily, member 17 | BCM | CD269 | TNFRSF13a | tumor necrosis factor receptor superfamily
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Natural/Endogenous Ligands Click here for help
APRIL {Sp: Human}
BAFF {Sp: Human}
Adaptor proteins (Human)

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
belantamab mafodotin Peptide Approved drug Immunopharmacology Ligand Hs Binding >9.8 pKd 1
pKd >9.8 (Kd <1.5x10-10 M) [1]
linvoseltamab Peptide Click here for species-specific activity table Hs Binding 7.6 pEC50 2
pEC50 7.6 (EC50 2.28x10-8 M) [2]
Description: BCMA binding in OPM-2 human myeloma cells.
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
APRIL {Sp: Human} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Immunopharmacology Ligand Hs - - -
BAFF {Sp: Human} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Immunopharmacology Ligand Hs - - -
Immunopharmacology Comments
B-cell maturation antigen (BCMA) is a cell surface receptor for B-cell activating factor (BAFF). It interacts with various TRAF family adaptor proteins to modulate cell survival and proliferation, via NF-κB and MAPK8/JNK signal transduction pathways. BCMA is highly plasma cell-selective for malignant plasma cells from multiple myeloma (MM) patients, and is being investigated as a target for therapies to tackle relapsed/refractory MM [3,5]. Novel BCMA-directed therapeutic agents in early stage development for MM include monoclonal antibodies and CAR-T cells [4,6,8]. The antibody-drug conjugate belantamab mafodotin (GSK2857916) [7] is one of the early phase anti-BCMA clinical candidates that is being evaluated in patients with relapsed/refractory MM.
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation


Show »

1. Algate P, Clegg SJ, Craigen JL, Hamblim PA, Lewis AP, Mayes P, Parmar RS, WattamTAK. (2016) B cell maturation antigen (BCMA) binding proteins. Patent number: US9273141B2. Assignee: Glaxo Group Ltd. Priority date: 27/05/2011. Publication date: 01/03/2016.

2. DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S et al.. (2021) A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv, 5 (5): 1291-1304. [PMID:33651100]

3. Hengeveld PJ, Kersten MJ. (2015) B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J, 5: e282. [PMID:25723853]

4. Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. (2017) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia, 31 (8): 1743-1751. [PMID:28025583]

5. Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM et al.. (2016) Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol, 174 (6): 911-22. [PMID:27313079]

6. Podar K, Pecherstorfer M. (2017) Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother, 18 (11): 1061-1079. [PMID:28604120]

7. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W et al.. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 123 (20): 3128-38. [PMID:24569262]

8. (2017) Sending CAR T Cells After Multiple Myeloma. Cancer Discov, 7 (8): OF9. [PMID:28588060]


Show »

How to cite this page